Ruxolitinib intermediate, identified by the CAS number 1236033-04-7, is a chemical compound that serves as a precursor in the synthesis of Ruxolitinib, a selective inhibitor of Janus kinases (JAKs). This intermediate typically exhibits characteristics common to organic compounds, including a defined molecular structure that facilitates its role in chemical reactions. It may possess functional groups that are reactive, allowing for further transformations during the synthesis process. The compound is likely to be solid at room temperature and may have specific solubility properties in various solvents, which are important for its handling and application in pharmaceutical manufacturing. Safety data sheets would provide information on its toxicity, stability, and proper handling procedures, which are crucial for laboratory and industrial environments. Overall, Ruxolitinib intermediate is integral to the production of Ruxolitinib, contributing to its therapeutic efficacy in treating conditions like myelofibrosis and polycythemia vera.

Ruxolitinib intermediate

1236033-04-7: Ruxolitinib intermediate, identified by the CAS number 1236033-04-7, is a chemical compound that serves as a precursor in the synthesis of Ruxolitinib, a selective inhibitor of Janus kinases (JAKs). This intermediate typically exhibits characteristics common to organic compounds, including a defined molecular structure that facilitates its role in chemical reactions. It may possess functional groups that are reactive, allowing for further transformations during the synthesis process. The compound is likely to be solid at room temperature and may have specific solubility properties in various solvents, which are important for its handling and application in pharmaceutical manufacturing. Safety data sheets would provide information on its toxicity, stability, and proper handling procedures, which are crucial for laboratory and industrial environments. Overall, Ruxolitinib intermediate is integral to the production of Ruxolitinib, contributing to its therapeutic efficacy in treating conditions like myelofibrosis and polycythemia vera.

CAS 1236033-04-7

Ruxolitinib intermediate

Ruxolitinib Impurity 25 (+)-Dibenzoyltartaric Acid Salt

Ref: 4Z-R-093040

Ruxolitinib Dibenzoyl SEM Pyrimidine Impurity

Ref: ST-EA-CP-R53078